This focused issue on “Urothelial Carcinoma”is edited by Dr. Ja Hyeon Ku, from Department of Urology, Seoul National University College of Medicine, South Korea; and Dr. Hyung Suk Kim, from Department of Urology, Dongguk University Ilsan Medical Center, Goyang, South Korea.
Dr. Ja Hyeon Ku graduated from Soonchunhyang University School of Medicine (Seoul, South Korea) in 1995. He was trained as a Urology Residency at Soonchunhyang University Hospital from 1996 to 2000, and finally acquired the urology board in 2000. He further completed Urology Fellowship at Seoul National University Hospital between 2003 and 2005. He obtained his PhD degree in Department of Urology at Seoul National University College of Medicine in 2005. Dr. Ku has been the faculty member and professor in the Department of Urology, Seoul National University College of Medicine since 2007. He also worked as a visiting postdoctoral fellow at Scott Department of Urology, Baylor College of Medicine under Dr. Seth P. Lerner from 2011 to 2012 (Texas, U.S). His clinical and research interests and are primarily focused on urologic oncology, particularly urothelial carcinoma of upper urinary tract and urinary bladder. His area of clinical activities also includes other major urological cancer, including prostate cancer and kidney cancer.
Dr. Hyung Suk Kim is an Assistant Professor of the Department of Urology at Dongguk University Ilsan Medical Center and Dongguk University College of Medicine, Goyang, Korea. He graduated from Seoul National University College of Medicine, Korea (2006). After he received a Medical Doctor degree in 2006, He completed his residency in the Seoul National University Hospital and obtained his board certification in Urology in 2011. Also, he completed fellowship training in urologic oncology and endourology in Seoul National University Hospital, and obtained his Master degree and Ph.D. degree (2018) in Medical Sciences from the Seoul National University College of Medicine. His research interest lies in Endourology and Urologic oncology. He has authored more than 40 peer-reviewed publications in domestic or international journals in these fields. He is a member of several professional organization including The Korean Urological Association (KUA), The Korean Endourological Society (KES), and The Korean Urological Oncology Society (KUOS).
- Focused issue outline:
- Role of immunotherapy in BCG unresponsive NMIBC
- Perioperative immunotherapy in MIBC
- Molecular subtypes of NMIBC
- Molecular subtypes of MIBC
- Androgen and estrogen receptor targeted treatment on bladder cancer
- Neoadjuvant chemotherapy on upper tract urothelial carcinoma
- Radiotherapy Management of Bladder Cancer
- DNA methylation based detection of urologic cancer in urine
- Urinary exosomal proteins as cancer biomarkers in urologic cancer
- The therapeutic strategies beyond BCG in the management of non-muscle invasive bladder cancer
- The clinical role of bladder preservation strategies in the management of muscle-invasive bladder cancer
- The current perspectives on novel systemic therapeutic agents beyond immune checkpoint inhibition in metastatic urothelial carcinoma
- Nephron-sparing approaches in the management of upper tract urothelial carcinoma: indications and clinical outcomes
- The prognostic role of steroid-hormone receptor signaling pathways in urothelial carcinoma
- The clinical and prognostic role of epigenetic alterations in urothelial carcinoma
- The clinico-pathological and prognostic features of non-urothelial carcinomas of the bladder
- The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma